Cargando…
Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas
INTRODUCTION: Human epidermal growth factor receptor (HER)-2 overexpression or gene amplification is more common in high-grade or type 2 endometrial carcinomas. We assessed the discordance of HER-2 expression between primary and metastatic or recurrent endometrial carcinomas. MATERIALS AND METHODS:...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742156/ https://www.ncbi.nlm.nih.gov/pubmed/23950654 http://dx.doi.org/10.2147/OTT.S47504 |
_version_ | 1782280322123038720 |
---|---|
author | Kato, Rina Hasegawa, Kiyoshi Ishii, Risa Owaki, Akiko Torii, Yutaka Oe, Shuko Hirasawa, Hiroshi Kobayashi, Yoichi Udagawa, Yasuhiro |
author_facet | Kato, Rina Hasegawa, Kiyoshi Ishii, Risa Owaki, Akiko Torii, Yutaka Oe, Shuko Hirasawa, Hiroshi Kobayashi, Yoichi Udagawa, Yasuhiro |
author_sort | Kato, Rina |
collection | PubMed |
description | INTRODUCTION: Human epidermal growth factor receptor (HER)-2 overexpression or gene amplification is more common in high-grade or type 2 endometrial carcinomas. We assessed the discordance of HER-2 expression between primary and metastatic or recurrent endometrial carcinomas. MATERIALS AND METHODS: Thirty-six primary, along with 14 metastatic and five recurrent tumors (matched to primaries), pathologically confirmed as high-grade or type 2 endometrial carcinomas, were submitted for immunohistochemistry (IHC) for HER-2. Fluorescence in situ hybridization was performed when the tumors showed HER-2 overexpression (≥2+ IHC score). The results of the IHC and fluorescence in situ hybridization assays were compared between the primary and metastatic or recurrent tumors. The relationships between HER-2 expression and clinicopathological factors or prognosis were investigated. RESULTS: HER-2 overexpression and HER-2 amplification (a ratio of HER-2 copies to chromosome 17 [CEP17] copies ≥2.2) were detected in 33.3% (twelve of 36 patients) and 5.6% (two of 36 patients) of primary tumors, respectively. HER-2 overexpression was not associated with clinicopathological factors or prognosis. In 19 tumor specimens obtained from metastatic or recurrent tumors, HER-2 overexpression and HER-2 amplification were detected in 57.9% (eleven patients) and 15.8% (three patients), respectively. HER-2 overexpression tended to predict a worse prognosis. CONCLUSION: HER-2 expression in metastatic or recurrent tumors was more frequent than in matched primary high-grade or type 2 endometrial carcinomas. Trastuzumab in combination with cytotoxic chemotherapy may represent an alternative therapeutic option for these tumors. |
format | Online Article Text |
id | pubmed-3742156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-37421562013-08-15 Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas Kato, Rina Hasegawa, Kiyoshi Ishii, Risa Owaki, Akiko Torii, Yutaka Oe, Shuko Hirasawa, Hiroshi Kobayashi, Yoichi Udagawa, Yasuhiro Onco Targets Ther Original Research INTRODUCTION: Human epidermal growth factor receptor (HER)-2 overexpression or gene amplification is more common in high-grade or type 2 endometrial carcinomas. We assessed the discordance of HER-2 expression between primary and metastatic or recurrent endometrial carcinomas. MATERIALS AND METHODS: Thirty-six primary, along with 14 metastatic and five recurrent tumors (matched to primaries), pathologically confirmed as high-grade or type 2 endometrial carcinomas, were submitted for immunohistochemistry (IHC) for HER-2. Fluorescence in situ hybridization was performed when the tumors showed HER-2 overexpression (≥2+ IHC score). The results of the IHC and fluorescence in situ hybridization assays were compared between the primary and metastatic or recurrent tumors. The relationships between HER-2 expression and clinicopathological factors or prognosis were investigated. RESULTS: HER-2 overexpression and HER-2 amplification (a ratio of HER-2 copies to chromosome 17 [CEP17] copies ≥2.2) were detected in 33.3% (twelve of 36 patients) and 5.6% (two of 36 patients) of primary tumors, respectively. HER-2 overexpression was not associated with clinicopathological factors or prognosis. In 19 tumor specimens obtained from metastatic or recurrent tumors, HER-2 overexpression and HER-2 amplification were detected in 57.9% (eleven patients) and 15.8% (three patients), respectively. HER-2 overexpression tended to predict a worse prognosis. CONCLUSION: HER-2 expression in metastatic or recurrent tumors was more frequent than in matched primary high-grade or type 2 endometrial carcinomas. Trastuzumab in combination with cytotoxic chemotherapy may represent an alternative therapeutic option for these tumors. Dove Medical Press 2013-08-07 /pmc/articles/PMC3742156/ /pubmed/23950654 http://dx.doi.org/10.2147/OTT.S47504 Text en © 2013 Kato et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Kato, Rina Hasegawa, Kiyoshi Ishii, Risa Owaki, Akiko Torii, Yutaka Oe, Shuko Hirasawa, Hiroshi Kobayashi, Yoichi Udagawa, Yasuhiro Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas |
title | Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas |
title_full | Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas |
title_fullStr | Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas |
title_full_unstemmed | Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas |
title_short | Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas |
title_sort | human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742156/ https://www.ncbi.nlm.nih.gov/pubmed/23950654 http://dx.doi.org/10.2147/OTT.S47504 |
work_keys_str_mv | AT katorina humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas AT hasegawakiyoshi humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas AT ishiirisa humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas AT owakiakiko humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas AT toriiyutaka humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas AT oeshuko humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas AT hirasawahiroshi humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas AT kobayashiyoichi humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas AT udagawayasuhiro humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas |